| Stereochemistry | ABSOLUTE |
| Molecular Formula | C43H59NO16 |
| Molecular Weight | 845.9257 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 11 / 11 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]4(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]5OC[C@@]25OC(=O)OC)C4(C)C
InChI
InChIKey=AHXICHPPXIGCBN-GPWPDEGDSA-N
InChI=1S/C43H59NO16/c1-21-24(57-35(50)28(47)31(38(3,4)5)44-36(51)59-39(6,7)8)19-43(53)33(58-34(49)23-16-14-13-15-17-23)30-41(11,32(48)29(56-22(2)45)27(21)40(43,9)10)25(46)18-26-42(30,20-55-26)60-37(52)54-12/h13-17,24-26,28-31,33,46-47,53H,18-20H2,1-12H3,(H,44,51)/t24-,25-,26+,28+,29+,30-,31+,33-,41+,42-,43+/m0/s1
| Molecular Formula | C43H59NO16 |
| Molecular Weight | 845.9257 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 10 / 11 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Bristol-Myers Squibb developed BMS-275183 for cancer indications. BMS 275183 is an inhibitor of tubulin polymerization. The drug participated in phase II clinical trials for patients with non-small cell lung cancer and in phase I for patients with advanced cancer. However, further development has been discontinued.
